Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVNRY Bavarian Nordic	$8.84 +0.1%	$8.62	$6.60 ▼ $14.60	$2.09B	1.36	2,948 shs	645 shs
HALO Halozyme Therapeutics	$54.05 +0.4%	$55.49	$42.01 ▼ $70.51	$6.65B	1.15	1.76 million shs	868,065 shs
RGEN Repligen	$127.36 +0.3%	$126.70	$102.97 ▼ $182.52	$7.16B	1.11	729,442 shs	208,766 shs
TECH Bio-Techne	$53.14 -0.1%	$49.94	$46.01 ▼ $83.62	$8.33B	1.39	1.46 million shs	843,085 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVNRY Bavarian Nordic	0.00%	+0.17%	-3.18%	+28.12%	+4.84%
HALO Halozyme Therapeutics	0.00%	+3.52%	+0.93%	-9.57%	+3.92%
RGEN Repligen	0.00%	+3.08%	+0.52%	+13.78%	+5.46%
TECH Bio-Techne	0.00%	+2.50%	+9.99%	+2.74%	-25.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	4.823 of 5 stars	3.1	1.0	0.0	4.4	2.0	2.5	4.4
RGEN Repligen	4.8146 of 5 stars	4.3	2.0	0.0	4.5	2.8	1.7	1.9
TECH Bio-Techne	4.974 of 5 stars	4.2	5.0	1.7	4.2	3.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVNRY Bavarian Nordic	0.00	N/A	N/A	N/A
HALO Halozyme Therapeutics	2.17	Hold	$61.90	14.52% Upside
RGEN Repligen	2.69	Moderate Buy	$172.83	35.70% Upside
TECH Bio-Techne	2.45	Hold	$72.00	35.50% Upside

Current Analyst Ratings Breakdown

Latest BVNRY, TECH, HALO, and RGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	RGEN Repligen	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$150.00
6/5/2025	TECH Bio-Techne	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
5/30/2025	TECH Bio-Techne	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$59.00
5/29/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00
5/14/2025	HALO Halozyme Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$73.00 ➝ $62.00
5/13/2025	HALO Halozyme Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
5/13/2025	HALO Halozyme Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform	$47.00
5/9/2025	TECH Bio-Techne	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$95.00 ➝ $70.00
5/8/2025	TECH Bio-Techne	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$72.00 ➝ $63.00
5/8/2025	TECH Bio-Techne	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$75.00 ➝ $60.00
5/8/2025	TECH Bio-Techne	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$95.00 ➝ $75.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVNRY Bavarian Nordic	$829.12M	2.52	$1.01 per share	8.73	$6.99 per share	1.26
HALO Halozyme Therapeutics	$1.02B	6.56	$4.66 per share	11.61	$2.86 per share	18.90
RGEN Repligen	$634.44M	11.28	$3.10 per share	41.03	$35.21 per share	3.62
TECH Bio-Techne	$1.16B	7.19	$2.31 per share	22.97	$13.13 per share	4.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVNRY Bavarian Nordic	$143.26M	$0.80	11.05	8.42	N/A	21.11%	11.89%	9.32%	8/22/2025 (Estimated)
HALO Halozyme Therapeutics	$444.09M	$3.76	14.38	8.69	0.36	44.76%	136.91%	26.05%	8/5/2025 (Estimated)
RGEN Repligen	-$25.51M	-$0.45	N/A	53.97	3.65	-3.93%	4.53%	3.17%	7/29/2025 (Estimated)
TECH Bio-Techne	$168.10M	$0.82	64.80	26.97	2.53	10.89%	13.17%	10.17%	8/6/2025 (Estimated)

Latest BVNRY, TECH, HALO, and RGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	RGEN Repligen	$0.40	N/A	N/A	N/A	$174.62 million	N/A
5/9/2025	Q1 2025	BVNRY Bavarian Nordic	N/A	$0.13	N/A	$0.13	N/A	$189.89 million
5/7/2025	Q3 2025	TECH Bio-Techne	$0.51	$0.56	+$0.05	$0.14	$317.92 million	$316.18 million
5/6/2025	Q1 2025	HALO Halozyme Therapeutics	$0.98	$1.11	+$0.13	$0.93	$231.21 million	$264.86 million
4/29/2025	Q1 2025	RGEN Repligen	$0.35	$0.39	+$0.04	$0.10	$163.65 million	$169.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
RGEN Repligen	N/A	N/A	N/A	N/A	N/A
TECH Bio-Techne	$0.32	0.60%	N/A	39.02%	N/A

Latest BVNRY, TECH, HALO, and RGEN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/19/2025	TECH Bio-Techne	quarterly	$0.08	0.67%	5/19/2025	5/19/2025	5/30/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVNRY Bavarian Nordic	N/A	2.81	1.44
HALO Halozyme Therapeutics	3.13	8.39	7.30
RGEN Repligen	0.27	6.79	5.79
TECH Bio-Techne	0.16	3.71	2.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVNRY Bavarian Nordic	N/A
HALO Halozyme Therapeutics	97.79%
RGEN Repligen	97.64%
TECH Bio-Techne	98.95%

Insider Ownership

Company	Insider Ownership
BVNRY Bavarian Nordic	N/A
HALO Halozyme Therapeutics	2.40%
RGEN Repligen	1.20%
TECH Bio-Techne	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVNRY Bavarian Nordic	1,611	236.57 million	N/A	Not Optionable
HALO Halozyme Therapeutics	390	123.22 million	120.26 million	Optionable
RGEN Repligen	1,778	56.18 million	55.51 million	Optionable
TECH Bio-Techne	3,100	156.77 million	150.65 million	Optionable

BVNRY, TECH, HALO, and RGEN Headlines

Recent News About These Companies

New York State Teachers Retirement System Has $8.18 Million Stock Holdings in Bio-Techne Corp (NASDAQ:TECH)

July 5 at 4:26 AM | marketbeat.com

KBC Group NV Sells 5,601 Shares of Bio-Techne Corp (NASDAQ:TECH)

July 5 at 4:11 AM | marketbeat.com

1 S&P 500 Stock to Research Further and 2 to Keep Off Your Radar

July 3 at 3:14 PM | finance.yahoo.com

Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock - Nasdaq

July 2, 2025 | nasdaq.com

Allspring Global Investments Holdings LLC Sells 116,204 Shares of Bio-Techne Corp (NASDAQ:TECH)

July 1, 2025 | marketbeat.com

Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock

June 30, 2025 | zacks.com

Sumitomo Mitsui Trust Group Inc. Has $119.05 Million Stake in Bio-Techne Corp (NASDAQ:TECH)

June 30, 2025 | marketbeat.com

Bio-Techne Corp (NASDAQ:TECH) Shares Sold by Bessemer Group Inc.

June 30, 2025 | marketbeat.com

Asset Management One Co. Ltd. Has $8.01 Million Stock Holdings in Bio-Techne Corp (NASDAQ:TECH)

June 28, 2025 | marketbeat.com

Bio-Techne Corporation (TECH) Stock Price, Quote, News & Analysis - Seeking Alpha

June 27, 2025 | seekingalpha.com

13,589 Shares in Bio-Techne Corp (NASDAQ:TECH) Acquired by Lecap Asset Management Ltd.

June 26, 2025 | marketbeat.com

Bio-Techne, USP Partner to Enhance Monoclonal Antibody, Gene Therapy Development

June 25, 2025 | insidermonkey.com

Is Bio-Techne Stock Underperforming the Nasdaq?

June 25, 2025 | finance.yahoo.com

Bio-Techne Corporation: Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

June 24, 2025 | finanznachrichten.de

Bio-Techne and USP to accelerate monoclonal antibody and gene therapy product development

June 24, 2025 | msn.com

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

June 24, 2025 | prnewswire.com

Bio-Techne Corp (NASDAQ:TECH) Shares Sold by Envestnet Portfolio Solutions Inc.

June 24, 2025 | marketbeat.com

Bio-Techne Corp (NASDAQ:TECH) Position Cut by Farther Finance Advisors LLC

June 22, 2025 | marketbeat.com

Bio-Techne Corp (NASDAQ:TECH) Shares Sold by Riverbridge Partners LLC

June 20, 2025 | marketbeat.com

Mn Services Vermogensbeheer B.V. Sells 6,200 Shares of Bio-Techne Corp (NASDAQ:TECH)

June 18, 2025 | marketbeat.com

Bio-Techne Corp (NASDAQ:TECH) Receives Consensus Rating of "Hold" from Brokerages

June 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Don’t Miss These 2 Small Quantum Stocks Poised to Pop
By Gabriel Osorio-Mazilli | June 24, 2025
View Don’t Miss These 2 Small Quantum Stocks Poised to Pop
3 Reasons AMD Could Be the Hottest Stock of the Summer
By Sam Quirke | June 20, 2025
View 3 Reasons AMD Could Be the Hottest Stock of the Summer
Why Unity Software May Be the AI Breakout No One Saw Coming
By Gabriel Osorio-Mazilli | June 9, 2025
View Why Unity Software May Be the AI Breakout No One Saw Coming
Oracle Stock Boils Higher, $300 Price Target in Sight
By Thomas Hughes | June 25, 2025
View Oracle Stock Boils Higher, $300 Price Target in Sight
Snag These 3 Bargain Tech Stocks Before They Pop
By Gabriel Osorio-Mazilli | June 27, 2025
View Snag These 3 Bargain Tech Stocks Before They Pop

BVNRY, TECH, HALO, and RGEN Company Descriptions

Bavarian Nordic OTCMKTS:BVNRY

$8.84 +0.01 (+0.11%)

As of 07/3/2025 10:42 AM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Halozyme Therapeutics NASDAQ:HALO

$54.05 +0.21 (+0.39%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$54.05 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Repligen NASDAQ:RGEN

$127.36 +0.40 (+0.32%)

Closing price 07/3/2025 01:10 PM Eastern

Extended Trading

$127.36 0.00 (0.00%)

As of 07/3/2025 04:03 PM Eastern

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Bio-Techne NASDAQ:TECH

$53.14 -0.05 (-0.08%)

Closing price 07/3/2025 03:53 PM Eastern

Extended Trading

$53.14 0.00 (0.00%)

As of 07/3/2025 04:27 PM Eastern

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time